Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Drospirenone/estradiol/prasterone - ANI Pharmaceuticals/Pantarhei Bioscience

Drug Profile

Drospirenone/estradiol/prasterone - ANI Pharmaceuticals/Pantarhei Bioscience

Alternative Names: Androgen Restored Contraceptive; ARC; Female balance pill - ANI Pharmaceuticals/Pantarhei Bioscience; Pill-Plus; Triple OC

Latest Information Update: 03 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioSante Pharmaceuticals
  • Developer Pantarhei Bioscience
  • Class Androstenes; Androstenols; Antiandrogens; Estradiol congeners; Estrenes; Hormonal contraceptives; Hormonal replacements; Progesterone congeners; Small molecules
  • Mechanism of Action Dehydroepiandrosterone replacements; Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Female sexual dysfunction; Pregnancy

Most Recent Events

  • 03 Sep 2021 Drospirenone/estradiol/prasterone - ANI Pharmaceuticals/Pantarhei Bioscience is available for licensing in USA, Asia as of 04 Feb 2019. https://www.pantarheibio.com/pipeline/androgen-restored-contraception/ (Pantarhei Bioscience website, September 2021)
  • 31 Aug 2018 Androgen Restored Contraception is still in phase II/III trials for Female sexual dysfunction in Netherlands (Pantarhei Bioscience website, August 2018)
  • 31 Aug 2018 Pantarhei Biosciences plans a phase III trial (Pantarhei Bioscience website, August 2018)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top